|This Slide: #24 of 100|
Slide #24. Celgene Corporation — Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Celgene Corporation (NASDAQ:CELG)
Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Celgene Corporation (NASDAQ:CELG) entered into a global license agreement with Nogra Pharma Limited, a private pharmaceutical company based in Dublin, Ireland, to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease and other indications.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Co. manufactures products in the U.S., Puerto Rico and in four foreign countries. Co. has products in the following therapeutic classes: oncology; cardiovascular; and immunoscience. Co.'s products include: Opdivo; Eliquis; Orencia; Sprycel; Yervoy; Empliciti; Baraclude; the Reyataz Franchise; the Sustiva Franchise; and the Hepatitis C Franchise.
Celgene SEC Filing Email Alerts Service
Open the CELG Page at The Online Investor »
Hold (2.00 out of 4)
(ranked lower than approx. 97% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite